The end of the soap for the past fall. The French pharmaceutical group Sanofi announced on Wednesday the completion of the transfer of 50% of its subsidiary Opella, head of the Doliprane, to the American CD & R Fund, in a message published just before its general shareholders meeting.
Sanofi retains a 48.2% participation in Opella, which markets the treatment without a recipe, and the BPIFRANCE Public Investment Bank will have a 1.8% participation, said the press release.
In October 2024, responding to its innovative drug and vaccine concentration strategy, Sanofi announced that they are in exclusive negotiations to give Opella control.
The sale of Opella, which markets without recipe treatments, had been controversial in a restructuring context during certain Sanofi activities.
The most prescribed medication
In the field, the subsidiary employees had been on strike for several days.
Wishing guarantees about the future of French sites of Opella, without defeating foreign investors, the government had seen in the public bank participation a means to obtain a right of passage on the strategic guidelines taken by the new foreign shareholder.
According to an evaluation of health insurance in November, Doliprane, produced from Paracetamol, one of the most common analgesics, remains the most prescribed medication in France, with 300 million boxes, according to the data arrested in mid -2014. No other treatment exceeds the threshold of 100 million.
Opella, which has been activated in 100 countries, manages 13 production sites and employs 11,000 people. Its product portfolio has been reduced and had about 100 brands at the end of 2024.
Source: BFM TV
